Search

Displaying results 3061 - 3070 of 6951 in total
  1. Drug

    Garenoxacin

    go.drugbank.com/drugs/DB06160
    Experimental

    Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Target

    Inositol 1,4,5-trisphosphate-gated calcium channel ITPR1

    go.drugbank.com/bio_entities/BE0004522
    TargetTransporterHumans

    Inositol 1,4,5-trisphosphate-gated calcium channel that, upon inositol 1,4,5-trisphosphate binding, mediates calcium release from the endoplasmic reticulum (ER) (PubMed:10620513, PubMed:27108797). Undergoes conformational changes upon li...

    Synonyms: IP3 receptor isoform 1, Type 1 InsP3 receptor
  3. Drug

    L-Acetylleucine

    go.drugbank.com/drugs/DB16956
    ApprovedInvestigational

    DL-) form has been available in France since 1957 for the treatment of vertigo. … [A264439] In September 2024, the FDA approved levacetylleucine for the treatment of select patients with NPC.[L51444]

  4. Drug

    Sulfamoxole

    go.drugbank.com/drugs/DB08798
    Experimental

    Sulfamoxole is an antibacterial in the sulfonamide class.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    AZD 3355

    go.drugbank.com/drugs/DB05404
    Investigational

    AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.

    Categories: GABA-A Receptor Agonists
  6. Drug

    Zafirlukast

    go.drugbank.com/drugs/DB00549
    Approved

    Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. … Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily.

    Categories: Drugs for Obstructive Airway Diseases
  7. Drug

    Betrixaban

    go.drugbank.com/drugs/DB12364
    Approved

    for VTE [A27285]. … Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks

  8. Drug

    AT-301

    go.drugbank.com/drugs/DB16507
    Investigational

    AT-301 was under investigation in clinical trial NCT01675284 to evaluate the safety, reactogenicity, and humoral immune responses to an inactivated H5N1 influenza vaccine

    Categories: Experimental Unapproved Treatments for COVID-19
  9. Drug

    Ragweed pollen extract

    go.drugbank.com/drugs/DB05368
    ApprovedWithdrawn

    The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy.

  10. Drug

    Thenalidine

    go.drugbank.com/drugs/DB04826
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to concerns involving neutropenia.

    Categories: Antihistamines for Systemic Use, Antihistamines for Topical Use